19:13 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors In vitro and cell culture studies identified Hsp90B1 inhibitors that could help treat solid tumors. Chemical synthesis, in vitro binding and cell-based assays of resorcinol analogs yielded a compound that inhibited Hsp90B1 with...
19:02 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Prophage G-200: Ph II data

Agenus halted enrollment in an open-label, U.S. Phase II trial in about 165 patients with surgically resectable, recurrent GBM after a DSMB determined intradermal Prophage G-200 plus Avastin bevacizumab was unlikely to improve survival vs....
21:37 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

HS-410: Additional Ph I/II data

Data from 94 patients with intermediate- or high-risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor in the Phase II portion of a double-blind, U.S. Phase I/II trial showed that both...
01:48 , Dec 22, 2016 |  BC Innovations  |  Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Heat Biologics, University of Miami deal

Heat Biologics and the university partnered to develop vaccines to treat Zika, HIV, West Nile, dengue and yellow fever virus infections based on Heat’s heat shock 90 kDa protein beta 1 (Hsp90B1; GP96; GRP94) vaccine...
07:00 , Oct 25, 2016 |  BC Extra  |  Clinical News

Heat, UMiami seek to create fetal Zika vaccine

Heat Biologics Inc. (NASDAQ:HTBX) and the University of Miami said they are collaborating to develop vaccines targeting the Zika virus and other infectious diseases based on Heat's heat shock 90 kDa protein beta 1 (...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Heat Biologics, Adaptive Biotechnologies deal

Heat and Adaptive partnered to discover immune biomarkers for Heat’s immunotherapies, including HS-410. The partners will use Adaptive’s immunoSEQ, an immune profiling assay that identifies T and B cell receptors. HS-410 is in Phase...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Viagenpumatucel-L: Phase Ib/II resumed

Heat Biologics resumed enrollment in the Phase Ib portion of the open-label, U.S. Phase Ib/II DURGA trial evaluating once-weekly injections of 1x10 7 cells of HS-110 for 18 weeks plus Opdivo nivolumab. The decision...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

Viagenpumatucel-L: Phase Ib/II data

Top-line data from 3 patients with advanced NSCLC previously treated with >=1 prior therapy in the open-label, U.S. Phase Ib/II DURGA trial showed that once-weekly injections of 1x10 7 cells of HS-110 for 18 weeks...